Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

Chee Khoon Lee, David Goldstein, Emma Gibbs, Heikki Joensuu, John Zalcberg, Jaap Verweij, Paolo G. Casali, Robert G. Maki, Angela Cioffi, Grant McArthur, Sarah J. Lord, Desmond Yip, Yada Kanjanapan, Piotr Rutkowski

Research output: Contribution to journalArticle

Abstract

Purpose Metastatic gastrointestinal stromal tumour (GIST) is generally an incurable disease with variable response to imatinib. We aimed to develop prognostic nomograms to predict overall survival (OS) and progression-free survival (PFS) for patients treated with imatinib. Methods Nomograms were developed in a training cohort (n = 330) of patients treated in a randomised trial (EORTC-ISG-AGITG 62005 phase III study) using Cox regression models, and validated in patients (n = 236) treated in routine clinical care from six referral centres. Nomogram performance was assessed by calculating the c statistic. A classification based on the nomograms' scores was generated to group patients according to risk. Results Nomogram risk factors for OS and PFS were size of the largest metastasis, tumour genotype, primary tumour mitotic count, haemoglobin and blood neutrophil count at commencement of imatinib. The nomograms predicted survival with a c statistic of 0.75 (training) and 0.62 (validation) for OS, and 0.69 (training) and 0.62 (validation) for PFS. When tested in the validation cohort, the nomograms discriminated well the high and intermediate risk from low risk patients (hazard ratio [HR] for OS 3.83, 95% confidence interval [CI] 1.71-8.56; and 2.48, 95% CI 1.12-5.50; for PFS 2.84, 95% CI 1.66-4.87; and 1.45, 95% CI 0.87-2.41, respectively). Conclusion The nomograms predicted the risk of GIST progression and death with good discrimination of risk groups, and may be of value for patient counselling and risk stratification.

Original languageEnglish
Pages (from-to)852-860
Number of pages9
JournalEuropean Journal of Cancer
Volume51
Issue number7
DOIs
Publication statusPublished - May 1 2015

Keywords

  • Gastrointestinal stromal
  • Imatinib
  • Nomogram
  • Prognosis
  • tumour

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib'. Together they form a unique fingerprint.

  • Cite this

    Lee, C. K., Goldstein, D., Gibbs, E., Joensuu, H., Zalcberg, J., Verweij, J., Casali, P. G., Maki, R. G., Cioffi, A., McArthur, G., Lord, S. J., Yip, D., Kanjanapan, Y., & Rutkowski, P. (2015). Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 51(7), 852-860. https://doi.org/10.1016/j.ejca.2015.02.015